关于举行 2022 年度网上业绩说明会的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 25 日在巨潮资讯网（www.cninfo.com.cn）披露 2022 年年度报告及其摘要。为让广 大投资者更加深入、全面地了解公司 2022 年度经营情况，公司定于 2023 年 4 月 14 日（星期五）15:00-16:30 举办 2022 年度业绩说明会，与投资者进行互动交流。 一、业绩说明会召开的时间、地点、方式 1、会议召开时间：2023 年 4 月 14 日（星期五）15:00-16:30 股票代码：300363 股票简称：博腾股份 公告编号：2023-031 号 重庆博腾制药科技股份有限公司 欢迎广大投资者积极参与本次业绩说明会！ (问题征集专题页面二维码) 2、会议召开地点：全景网"投资者关系互动平台" 3、会议召开方式：视频及网络互动 二、出席人员 出席本次说明会的人员有：公司董事长、总经理居年丰先生，副总经理、财 务负责人陈晖先生，副总经理、董事会秘书皮薇女士，独立董事袁 ...

Group 1: Market Trends and Production Capacity - Overseas CDMO companies are experiencing price increases due to inflation, but strategies vary by business segment and market [1] - The capacity utilization rates of the three factories differ slightly, with the Jiangxi factory maintaining a high utilization rate, while the Changshou and Hubei factories are gradually filling their capacities [1] - The company’s formulation factory projects are currently all from domestic clients [2] Group 2: Project Developments and Future Plans - The Slovenia project, announced in 2022, is in the early engineering design phase and is expected to be operational by Q3 2024, serving as a research and production base in Europe [2] - The company is involved in the entire ADC service cycle due to its capabilities in small molecules [2] - The GCT business pipeline is primarily in the preclinical stage, with two client projects successfully applying for IND last year [3] Group 3: Business Strategy and Talent Expansion - The company’s new business layout is driven by both market demand and proactive planning [2] - In 2022, the company expanded its workforce by approximately 1,700 employees, with 2023 recruitment focusing on new business and capabilities [3] - The company plans to consider specific financing plans based on business needs [3] Group 4: Financial and Capital Expenditure - The company’s capital expenditure plan for 2022 was approximately 1.7 billion, with actual execution within this range [3] - The number of commercialized API projects remains in single digits, but the number of PV projects has reached several dozen over the past two years, with more commercial projects expected to materialize after 2024 [3]

Group 1: Business Operations - The company's intermediates business involves few pre-clinical products, primarily focusing on commercialized intermediates [1] - New drug application processes are mainly based on client-provided technology packages, which require multiple technical improvements for mass production [1] - The company is planning to implement stock incentives, but cannot review such matters within six months after terminating previous incentives [1] Group 2: Market and Revenue Insights - The revenue distribution for the first three quarters of the year is primarily from three major therapeutic areas: anti-HIV, anti-hepatitis C, and anti-diabetes [2] - The main contributor to anti-diabetes products in the first half of the year is Johnson & Johnson [2] - The company maintains its initial sales budget for the fourth quarter based on current order conditions [2] Group 3: Environmental and Compliance Risks - The company acknowledges environmental risks associated with its chemical production but has established a robust EHS management system to address these concerns [2] - Client audits are project-based and ongoing, rather than a one-time event [2] Group 4: Capacity and Expansion Plans - Currently, there are no plans for new workshops as existing capacity meets order demands [2] - The company does not have performance commitments from the acquired Jiangxi Dongbang Pharmaceutical Co., Ltd., as it is the largest customer of Dongbang [2]